Assembly Biosciences Inc (ASMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Assembly Biosciences Inc (ASMB) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.13 Million) by net assets ($182.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Assembly Biosciences Inc - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Assembly Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Assembly Biosciences Inc for a breakdown of total debt and financial obligations.
Assembly Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Assembly Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Hezong Science&Technology Co Ltd
SHE:300477
|
-0.169x |
|
Mahindra Logistics Limited
NSE:MAHLOG
|
-0.031x |
|
Shenke Slide Bearing Corp
SHE:002633
|
0.026x |
|
Andersen Group Inc.
NYSE:ANDG
|
-0.838x |
|
Masterwork Machinery
SHE:300195
|
0.014x |
|
Youlchon Chem
KO:008730
|
0.029x |
|
Smcp SAS
PA:SMCP
|
0.110x |
|
Wave Cyber Shanghai Co Ltd
SHG:688718
|
0.028x |
Annual Cash Flow Conversion Efficiency for Assembly Biosciences Inc (2008–2024)
The table below shows the annual cash flow conversion efficiency of Assembly Biosciences Inc from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see Assembly Biosciences Inc (ASMB) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $33.36 Million | $-51.12 Million | -1.532x | -376.89% |
| 2023-12-31 | $41.10 Million | $22.74 Million | 0.553x | +154.16% |
| 2022-12-31 | $82.66 Million | $-84.46 Million | -1.022x | -84.81% |
| 2021-12-31 | $168.93 Million | $-93.40 Million | -0.553x | -111.27% |
| 2020-12-31 | $240.58 Million | $-62.96 Million | -0.262x | +14.95% |
| 2019-12-31 | $273.22 Million | $-84.07 Million | -0.308x | +0.22% |
| 2018-12-31 | $210.65 Million | $-64.96 Million | -0.308x | -1975.30% |
| 2017-12-31 | $113.12 Million | $1.86 Million | 0.016x | +103.77% |
| 2016-12-31 | $79.88 Million | $-34.88 Million | -0.437x | -177.33% |
| 2015-12-31 | $118.74 Million | $-18.70 Million | -0.157x | +38.41% |
| 2014-12-31 | $58.57 Million | $-14.97 Million | -0.256x | +64.81% |
| 2013-12-31 | $24.49 Million | $-17.80 Million | -0.727x | +39.48% |
| 2012-12-31 | $17.81 Million | $-21.38 Million | -1.200x | -65.36% |
| 2011-12-31 | $34.53 Million | $-25.07 Million | -0.726x | -61.86% |
| 2010-12-31 | $11.63 Million | $-5.21 Million | -0.449x | -272.03% |
| 2009-12-31 | $-13.36 Million | $-3.48 Million | 0.261x | -40.55% |
| 2008-12-31 | $-9.46 Million | $-4.15 Million | 0.439x | -- |
About Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepat… Read more